Eli Lily (NYSE: LLY) could be one of the biggest comeback
story in 2014 among big pharmaceutical companies. Helping the case for Lily are
the recent positive news on its cancer drug Ramucirumab
and diabetes drug Dulaglutide.
News on Dulaglutide
(for people with Type 2 diabetes) showed that the results from its Phase III
trial AWARD-6 study indicates that it works as well as the market leading
therapy Victoza (from Novo Nordisk, NYSE: NVO). The
fact that Dulaglutide is a once-weekly
versus once-daily for Victoza would
help move patients over to the new drug from Lily.
News on Ramicirumab
showed that in a Phase III study on 1200 patients with non-small cell lung
cancer, a combination of ramucirumab,
chemotherapy and docetaxel improved
overall survival and met its primary end-point. More details on this study
would be released later.
LLY is up 15% YTD (till 02/26/2014) handily beating S&P
500 which is flat for the year till date (YTD) and I do not think it is done yet. Additionally it provides a juicy +3% yield. LLY is one of my favorite pharmaceutical plays for 2014.
No comments:
Post a Comment